Faculty of Medicine, Department of Ophthalmology, Baskent University, Fevzi Çakmak Caddesi, Bahçelievler, 06490, Ankara, Turkey.
Int Ophthalmol. 2023 Nov;43(11):3943-3952. doi: 10.1007/s10792-023-02796-x. Epub 2023 Jul 7.
To report our experience with the 2% cyclosporin A (CsA) in a series of challenging inflammatory ocular surface diseases due to different etiologies.
The records of patients who received topical 2% CsA for different indications were reviewed retrospectively. Demographic characteristics, indications for treatment, patient symptoms and clinical findings were recorded.
Fifty-two eyes of 52 patients were included. Mean age was 43.2 ± 14.3 (11-66) years with a F/M ratio of 34/18. Indications included pediatric acne rosacea (n = 4), adenoviral corneal subepithelial infiltrates (n = 12), filamentary keratitis (n = 14), pterygium recurrence (n = 15), herpetic marginal keratitis (n = 2) and graft versus host disease (n = 5 patients). Mean duration of treatment was 7.3 ± 2.8 (3-10) months. Forty-three (83%) patients reported favorable outcome with improvement in symptoms after a mean time of 4.4 ± 2.7 (2-6) months.
Topical 2% CsA may address the needs of different cases with ocular surface inflammation, as a safe option for long-term therapy.
报告我们在一系列因不同病因引起的具有挑战性的炎症性眼表疾病中使用 2%环孢素 A（CsA）的经验。
回顾性分析了因不同适应证接受局部 2%CsA 治疗的患者的病历。记录了患者的人口统计学特征、治疗适应证、患者症状和临床发现。
52 例患者的 52 只眼纳入研究。平均年龄为 43.2±14.3（11-66）岁，男女比例为 34/18。适应证包括儿童酒渣鼻（n=4）、腺病毒角膜上皮下浸润（n=12）、丝状角膜炎（n=14）、翼状胬肉复发（n=15）、单纯疱疹性边缘性角膜炎（n=2）和移植物抗宿主病（n=5 例）。平均治疗时间为 7.3±2.8（3-10）个月。43（83%）例患者在平均 4.4±2.7（2-6）个月后症状改善，报告治疗结果良好。
局部使用 2%CsA 可能满足不同眼表炎症患者的需求，是一种长期治疗的安全选择。
